Behandling af VLU'er med Aquacel® Ag+ Extra™ versus DACC-bandager var forbundet med
- Signifikant bedre komplet sårlukningsrate (74,8 %) i uge 12
- Betydeligt kortere sårlukningstid på 56 dage
- Signifikant større procentdel (85,2 %) reduktion i sårareal
- Signifikant højere rate (77,1 %) af tilfredsstillende kliniske fremskridt
- Lavere forekomst af bivirkninger
- Forbedret QoL13
BEC*, et overfladeaktivt stof, reducerer overfladespændingen for at forbedre anti-biofilm-ydeevnen af Aquacel® Ag+ Extra-bandagen™. 14,15,16
EDTA, et metalchelateringsmiddel, EDTA hjælper med at forstyrre biofilm ved at fjerne metalioner, der holder EPS-matrixen sammen for at udsætte mikroorganismer for de antimikrobielle virkninger af det ioniske sølv. 15,17,18,19
IONISK SØLV, Et bredspektret antimikrobielt middel indeholdt i en sikker og effektiv mængde (1,2%) sikrer celledød af de eksponerede bakterier ved at beskadige DNA'et, denaturere proteiner og enzymer og forstyrre proteinsyntesen. 4,20,21
Udviklingen af MORE THAN SILVER™-teknologien involverede forskning i en bred vifte af biofilmforstyrrende stoffer og overfladeaktive stoffer i kombination med ionisk sølv. 4
Ikke alle krav understøttes i alle lovgivningsmæssige geografiske områder.
1. Beraldo S. et al. The effectiveness of an improved silver-containing dressing in venous leg ulcers that are difficult to heal: a randomised controlled trial. Journal of Wound Care, 2025.
2. Meredith K, et al. Evaluation of the antibiofilm performance of silver-containing wound dressings: a biofilm model with two species. Cureus. 2024; 16(9):e70086.
3. Meredith et al. Evaluation of silver-containing gelling fibre dressings against antibiotic-resistant pathogens using an in vitro biofilm model. Infect Resist. 2023 Nov. 2;16:7015-7019.
4. Bowler PG & Parsons D. Combating wound biofilm and recalcitrance with a novel anti-biofilm hydrofiber® wound dressing. Wound Medicine 14 (2016) 6-11.
5. Rice JB et al. The burden of diabetic foot ulcers to Medicare and private insurance companies. Diabetes Care 2014; 37 (3):651-658.
6.Martinengo L et al. Prevalence of chronic wounds in the general population: systematic review and meta-analysis of observational studies. Ann Epidemiol 2019; 29:8-15.
7.Sen CK. Human wounds and their burden: Updated 2020 compendium of estimates. Adv Wound Care (New Rochelle) 2021; 10(5):281-292.
8.Olsson M et al. The humanistic and economic burden of chronic wounds: A systematic review. Wound Repair Regen 2019; 27(1):114-125.
9.Chan B et al. Studies of the disease costs of chronic wounds: a systematic review. J Wound Care 2017; 26(Suppl 4):S4-S14.
10. James GA et al. Biofilm in chronic wounds. Wound Repair Regen 2008; 16(1):37-44.
11. Malone M et al. The prevalence of biofilm in chronic wounds: a systematic review and meta-analysis of published data. J Wound Care 2017; 26(1):20-25.
12.1708881v1 Instructions for use, Convatec.
13.WC-22-435 clinical investigation report, Convatec 2024.
14. Priests. Composition consisting of antimicrobial metal ions and a quaternary cationic surfactant. WO2012136968A1.
15. Murphy et al. International consensus document. Embedding wound hygiene in a proactive wound healing strategy. J Wound Care 2022; 31:S1-S24.
16. Hall-Stoodley L I et al. Towards diagnostic guidelines for biofilm-associated infections. FEMS Immunol Med Microbiol. 2012; 65:127-145.
17. Wolcott RD et al. Studies of biofilm maturity indicate that sharp debridement opens a time-dependent therapeutic window. J Wound Care. 2010 Aug; 19(8):320-8.
18.Banin et al. Chelator-induced dispersal and killing of Pseudomonas aeruginosa cells in biofilm. Appl. Environ. Microbiol 2006; 72: 2064-2069.
19. Finnegan & Percival. EDTA: an antimicrobial and anti-biofilm agent for use in wound care. Adv Wound Care (New Rochelle) 2015; 4: 415-421.
20. Lansdown. Silver 1: Its antibacterial properties and mechanisms of action. J Wound Care 2002; 11: 125-130.
21. Lansdown. The role of silver. Eur Tissue Rep Soc 2002; 9: 108-111.
*BEC, benzethonium chloride
AP-73302-DNK-DAN-v1
® / ™ alle varemærker tilhører Convatec-koncernselskaber. ©2025 Convatec Inc.